A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Deuruxolitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Concert Pharmaceuticals
- 31 May 2023 Status changed from active, no longer recruiting to completed.
- 15 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2021 New trial record